NIH Blueprint MedTech Translator
Funds neurological device and therapy translation through milestone-based collaborative agreements.
NIH Blueprint MedTech Translator sits under NINDS as part of the NIH Blueprint Consortium. It supports translational work and clinical feasibility studies for therapeutic and diagnostic devices aimed at nervous system and neuromuscular disorders. The mechanism is UG3/UH3, a milestone-driven cooperative agreement, and the current NOFO is PAR-25-383. The program is open through January 29, 2028, uses a rolling cadence, and is open to U.S. universities, nonprofits, research organisations, and companies rather than individuals. That structure suits device teams that need staged translational support and a clear go-or-no-go path before larger clinical work. Strong applicants align the device to a neurological or neuromuscular use case, show that the project can move through the cooperative milestones, and keep the proposed work inside the specific device translation niche that the program is built for. The funding page places the program alongside other opportunities, which makes it a visible entry point for translational teams that need a nontraditional award structure.
Each grant below is a distinct funding opportunity with its own eligibility, scope, and deliverables.